Page last updated: 2024-10-28

hydroxyurea and Leukemia

hydroxyurea has been researched along with Leukemia in 106 studies

Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)

Research Excerpts

ExcerptRelevanceReference
"1 mM, hydroxyurea (HU) enhances the accumulation of cytosine arabinoside (ara-C) in leukemia cells in vitro."9.13Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. ( Camitta, B; Dubowy, R; Graham, M; Hakami, N; Kletzel, M; Mahoney, D; Newman, E; Ravindranath, Y, 2008)
" The aims of this study were (1) to detect involvement of N- and K-ras mutations in codons 12 and 13 in the pathogenesis of the chronic and blastic phases of PV and ET, (2) to study the occurrence of microsatellite instability (MSI) in chromosomes 5 and 7 during the chronic phase and blastic transformation of the disease, and (3) to examine the incidence of leukemia in patients treated with hydroxyurea (HU)."9.10Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. ( Loukopoulos, D; Madzourani, M; Mavrogianni, D; Meletis, J; Michali, E; Pangalis, G; Terpos, E; Vaiopoulos, G; Viniou, N; Yataganas, X, 2002)
"To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia."7.75A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009)
"Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)."7.72Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003)
"In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%."7.69Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996)
"From 1981 to 1995, we diagnosed, followed and treated at our institution fifty-eight cases of essential thrombocythemia (ET), using hydroxyurea (HU) as first-line therapy in these patients."7.69Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. ( Bordessoule, D; Brigaudeau, C; Desangles, F; Fermeaux, V; Liozon, E; Praloran, V; Trimoreau, F, 1997)
"Hydroxyurea is an effective agent in the treatment of PV, but continued assessment of its mutagenic potential is necessary."5.27Treatment of polycythemia vera with hydroxyurea. ( Berk, PD; Donovan, PB; Goldberg, JD; Kaplan, ME; Knospe, WH; Laszlo, J; Mack, K; Najean, Y; Silberstein, EB; Tatarsky, I, 1984)
"1 mM, hydroxyurea (HU) enhances the accumulation of cytosine arabinoside (ara-C) in leukemia cells in vitro."5.13Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. ( Camitta, B; Dubowy, R; Graham, M; Hakami, N; Kletzel, M; Mahoney, D; Newman, E; Ravindranath, Y, 2008)
" The aims of this study were (1) to detect involvement of N- and K-ras mutations in codons 12 and 13 in the pathogenesis of the chronic and blastic phases of PV and ET, (2) to study the occurrence of microsatellite instability (MSI) in chromosomes 5 and 7 during the chronic phase and blastic transformation of the disease, and (3) to examine the incidence of leukemia in patients treated with hydroxyurea (HU)."5.10Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. ( Loukopoulos, D; Madzourani, M; Mavrogianni, D; Meletis, J; Michali, E; Pangalis, G; Terpos, E; Vaiopoulos, G; Viniou, N; Yataganas, X, 2002)
"We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis."5.09Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000)
"To compare by a prospective study in high risk polycythemia vera (PV) patients 33P alone and 32P followed by low-dose hydroxyurea (HU) maintenance therapy."5.08[Treatment of polycythemia. I--Using radiophosphorus with or without treatment in 483 patients over 65 years of age]. ( Dupuy, E; Goguel, A; Grange, MJ; Mougeot-Martin, M; Najean, Y; Rain, JD; Vigneron, N, 1998)
"A 62-year-old man with refractory leukemia transformed from myelodysplastic syndrome was placed on hydroxyurea (hydroxycarbamide) at a daily dose of 500 mg."4.90[Hydroxyurea (hydroxycarbamide)-induced hepatic dysfunction confirmed by drug-induced lymphocyte stimulation test]. ( Karigane, D; Kikuchi, T; Koda, Y; Mori, T; Nakajima, H; Okamoto, S; Shimizu, T; Toyama, T, 2014)
" Purine antimetabolites used in the treatment of leukemia can be grouped into three classes: (1) structural analogs of normal purines (6-mercaptopurine and 6-thioguanine); (2) inhibitors of de novo purine biosynthesis (methotrexate and hydroxyurea); and (3) inhibitors of purine salvage (2'-deoxycoformycin)."4.77Purine metabolism as a target for leukemia chemotherapy. ( Brouns, MC; Fitchen, JH; Riscoe, MK, 1989)
"To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia."3.75A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009)
"Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)."3.72Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003)
"In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%."3.69Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996)
"From 1981 to 1995, we diagnosed, followed and treated at our institution fifty-eight cases of essential thrombocythemia (ET), using hydroxyurea (HU) as first-line therapy in these patients."3.69Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. ( Bordessoule, D; Brigaudeau, C; Desangles, F; Fermeaux, V; Liozon, E; Praloran, V; Trimoreau, F, 1997)
"While studying the effects of chemotherapy on glucocorticoid receptor (GR) binding levels in hematological malignancies, we observed a sizable increase in nuclear GR binding of [3H]dexamethasone in peripheral leukocytes from a chronic basophilic leukemia patient following treatment with hydroxyurea plus prednisone, but not after prednisone alone."3.67Elevated glucocorticoid receptor binding in cultured human lymphoblasts following hydroxyurea treatment: lack of effect on steroid responsiveness. ( Greipp, PR; Hoagland, HC; Littlefield, BA, 1986)
"The induction of erythroid differentiation in the T3-C12 clone of Friend leukemia cells by dimethyl sulfoxide is accompanied by reduction in viral RNA-dependent DNA polymerase activity with increased cellular delta-aminolevulinic acid synthetase activity and hemoglobin synthesis."3.65Erythroid differentiation in cultured Friend leukemia cells treated with metabolic inhibitors. ( Buell, DN; Ebert, PS; Wars, I, 1976)
"Acetohydroxamic acid has been identified, by paper chromatography, in the blood of three patients with chronic myelogenous leukemia on hydroxyurea therapy."3.64HYDROXYUREA: MECHANISM OF ACTION. ( CARBONE, PP; FISHBEIN, WN, 1963)
"Hyperleukocytosis is defined as a white blood cell count greater than 100."2.58The management of hyperleukocytosis in 2017: Do we still need leukapheresis? ( Korkmaz, S, 2018)
"Hyperleukocytosis, arbitrarily defined in acute leukemia as a white blood cell count greater than 100,000/mL, often is associated with increased morbidity and mortality in patients with leukemic processes."2.48Hyperleukocytosis, leukostasis and leukapheresis: practice management. ( Becker, J; Ganzel, C; Lazarus, HM; Mintz, PD; Rowe, JM, 2012)
"Hydroxyurea has proven clinical efficacy for reducing acute vaso-occlusive events including pain episodes and acute chest syndrome."2.45Advances in the use of hydroxyurea. ( Aygun, B; Ware, RE, 2009)
"Hydroxyurea (HU) has a limited, if any, leukemogenic potential and should be considered the current cytotoxic drug for patients at high risk for thrombotic complications, ie, those with age above 60 years or previous thrombotic events."2.42The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? ( Barbui, T, 2004)
"Its use in the treatment of essential thrombocythemia began later in 1950."2.41Treatment of the myeloproliferative disorders with 32P. ( Berlin, NI, 2000)
"Major bleeding is rare and seem to be related to higher platelet counts: therefore, a platelet count over 1500 x 10(9)/L is generally regarded as an indication for cytoreduction."2.39Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996)
"Acute leukemia is an uncommon complication of patients with essential thrombocythemia (ET)."1.33Acute biphenotypic leukemia arising in a patient with essential thrombocythemia. ( Lee, LH; Wong, GC, 2006)
"The median age at malignancy diagnosis was 34 years (range, 14 months-62 years)."1.32Malignancy in patients with sickle cell disease. ( Schultz, WH; Ware, RE, 2003)
" Thus, the efficacy of other antileukemic agents combined with ZOL should be evaluated experimentally."1.32Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. ( Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Ottmann, OG; Sato, K; Segawa, H; Yuasa, T, 2004)
" The cytotoxic effects of STI571 were studied in combination with antileukemic agents against Ph(+) leukemia cell lines, KU812, K-562, TCC-S, and TCC-Y."1.31In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. ( Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S, 2001)
"Hydroxyurea is an effective agent in the treatment of PV, but continued assessment of its mutagenic potential is necessary."1.27Treatment of polycythemia vera with hydroxyurea. ( Berk, PD; Donovan, PB; Goldberg, JD; Kaplan, ME; Knospe, WH; Laszlo, J; Mack, K; Najean, Y; Silberstein, EB; Tatarsky, I, 1984)
"Cytogenetic studies of chronic myelogenous leukemia (CML) have shown that the majority of hemopoietic cells originate from pluripotential stem cells affected in this disease."1.26Philadelphia-chromosome-positive pre-B-cell leukemia presenting as blast crisis of chronic myelogenous leukemia. ( Brattain, MG; Coleman, MS; Crist, WM; Sarrif, A; Vinson, PC; Vogler, LB, 1979)

Research

Studies (106)

TimeframeStudies, this research(%)All Research%
pre-199047 (44.34)18.7374
1990's20 (18.87)18.2507
2000's29 (27.36)29.6817
2010's7 (6.60)24.3611
2020's3 (2.83)2.80

Authors

AuthorsStudies
Torre, EA1
Kersh, AE1
Fischer, AS1
Xu, X1
Rosenbach, M1
Shields, BE1
Hobbs, LK1
Carr, PC1
Gru, AA1
Flowers, RH1
Choi, HS1
Hong, J1
Hwang, SM1
Lee, JH1
Ma, Y1
Kim, SA1
Lee, JY1
Lee, JO1
Bang, SM1
Rider, TG1
George, SMC1
Batool, A1
Tidbury, HL1
Grace, RJ1
Newman, JA1
Ali, Z1
Felton, JR1
Korkmaz, S1
Shimizu, T1
Mori, T1
Karigane, D1
Kikuchi, T1
Koda, Y1
Toyama, T1
Nakajima, H1
Okamoto, S1
Roufosse, F1
Li, QB1
Li, L1
You, Y1
Chen, ZC1
Xia, LH1
Zou, P1
Ware, RE2
Aygun, B1
Mai, X1
Lu, X1
Xia, H1
Cao, Y1
Liao, Y1
Lv, X1
Ganzel, C1
Becker, J1
Mintz, PD1
Lazarus, HM1
Rowe, JM1
Lu, XZ1
Cai, XH1
Ma, LD1
Chen, BA1
Ellis, AK1
Lee, DH1
Spell, DW1
Nielsen, I1
Hasselbalch, HC1
FISHBEIN, WN1
CARBONE, PP1
ORIGENES, ML1
BEATTY, EC1
BRUBAKER, C1
HAMMOND, D1
HARTMANN, JR1
SHORE, N1
WILLIAMS, KO1
STEARNS, B1
LOSEE, KA1
BERNSTEIN, J1
FERNBACH, DJ1
SHULLENBERGER, CC1
KRAKOFF, IH1
SAVEL, H1
MURPHY, ML2
GOLDIN, A1
VENDITTI, JM1
MEAD, JA1
GLYNN, JP1
Schultz, WH1
Kimura, S1
Kuroda, J1
Segawa, H1
Sato, K1
Nogawa, M1
Yuasa, T1
Ottmann, OG1
Maekawa, T1
Barbui, T6
Bilousova, G1
Marusyk, A1
Porter, CC1
Cardiff, RD1
DeGregori, J1
Burkitt, MJ1
Raafat, A1
Kiladjian, JJ2
Rain, JD3
Bernard, JF1
Briere, J3
Chomienne, C1
Fenaux, P1
Silver, RT2
Wong, GC1
Lee, LH1
Dubowy, R1
Graham, M1
Hakami, N1
Kletzel, M1
Mahoney, D1
Newman, E1
Ravindranath, Y1
Camitta, B1
Lomen, PL1
Khilanani, P1
Kessel, D1
Böhmer, RM1
Donovan, PB3
Kaplan, ME2
Goldberg, JD3
Tatarsky, I1
Najean, Y2
Silberstein, EB1
Knospe, WH1
Laszlo, J1
Mack, K2
Berk, PD3
Pfeifle, CE2
Howell, SB2
Streifel, JA1
Paton, CM1
Bishop, JF1
Mathews, JD1
Whiteside, MG1
Silver, FS1
Espinoza, LR1
Hartmann, RC1
Abe, I1
Saito, S1
Hori, K1
Suzuki, M1
Sato, H1
Passe, S1
Miké, V1
Mertelsmann, R1
Gee, TS2
Clarkson, BD2
Chapman, RS1
Chresta, CM1
Herberg, AA1
Beere, HM1
Heer, S1
Whetton, AD1
Hickman, JA1
Dive, C1
Ho, PT1
Murgo, AJ1
Weinfeld, A1
Swolin, B1
Westin, J1
Boivin, P1
Fitzgerald, JM1
McCann, SR1
Nand, S2
Stock, W1
Godwin, J1
Fisher, SG2
Finazzi, G4
Dupuy, E2
Liozon, E1
Brigaudeau, C1
Trimoreau, F1
Desangles, F1
Fermeaux, V1
Praloran, V1
Bordessoule, D1
Tóth, G1
Schlammadinger, J1
Sipka, S1
Kiss, A1
Szegedi, G1
Rák, K1
Szabó, G1
Pearson, TC1
Green, AR1
Reilly, JT1
Harrisoni, G1
Cory, AH1
He, AW1
Cory, JG1
Randi, ML2
Rossi, C1
Fabris, F2
Girolami, A2
Berlin, NI2
Tefferi, A1
Solberg, LA1
Silverstein, MN1
Ruggeri, M1
Rodeghiero, F1
Lengfelder, E1
Hehlmann, R1
Ahlmann, M1
Lanvers, C1
Lümkemann, K1
Rössig, C1
Freund, A1
Baumann, M1
Boos, J1
Kano, Y1
Akutsu, M1
Tsunoda, S1
Mano, H1
Sato, Y1
Honma, Y1
Furukawa, Y1
Guilmin, F1
Goguel, A1
Grange, MJ1
Vigneron, N1
Mougeot-Martin, M1
Ikeda, Y1
de Montalembert, M1
Davies, SC1
Mavrogianni, D1
Viniou, N1
Michali, E1
Terpos, E1
Meletis, J1
Vaiopoulos, G1
Madzourani, M1
Pangalis, G1
Yataganas, X1
Loukopoulos, D1
Ebert, PS1
Wars, I1
Buell, DN1
Berg, J1
Vincent, PC4
Gunz, FW5
Vogler, LB1
Crist, WM1
Vinson, PC1
Sarrif, A1
Brattain, MG1
Coleman, MS1
Wollner, N1
Lieberman, P1
Exelby, P1
D'angio, G1
Burchenal, J1
Fang, S1
Chusid, MJ1
Dale, DC1
MacEwen, EG1
Drazner, FH1
McClelland, AJ1
Wilkins, RJ1
Liang, R1
Chan, TK1
Chiu, E1
Todd, D1
Grossi, A1
Vannucchi, AM1
Longo, G1
Rafanelli, D1
Rossi Ferrini, P1
Schafer, AI1
van den Anker-Lugtenburg, PJ1
Sizoo, W1
Messmore, H1
Bird, ML1
Schulz, W1
Fisher, RI1
Löfvenberg, E1
Nordenson, I1
Wahlin, A1
Hedley, D1
Rugg, C1
Musgrove, E1
Taylor, I1
Kubota, M2
Takimoto, T2
Tanizawa, A2
Akiyama, Y2
Mikawa, H2
Kitoh, T1
Kiriyama, Y1
Riscoe, MK1
Brouns, MC1
Fitchen, JH1
Fruchtman, SM1
Wasserman, LR2
Landaw, SA1
Littlefield, BA1
Hoagland, HC1
Greipp, PR1
Fram, RJ1
Kufe, DW1
Levi, JA3
Smith, RG1
Whang-Peng, J1
Gallo, RC1
Levine, P1
Ting, RC1
Pouillart, P1
Schwarzenberg, L2
Mathé, G2
Schneider, M2
Jasmin, C1
Hayat, M1
Weiner, R1
de Vassal, F1
Amiel, JL2
Beyer, HP1
Fajbisowicz, S1
Dowling, MD1
Haghbin, M1
Cunningham, B1
Tan, CT1
Burchenal, JH1
Prandota, J1
Brunning, RD1
Maurice, PA1
Lederrey, C1
Cattan, A1
Schlumberger, JR1
Benckhuijsen, C1
Kovaleva, LG1
Konior, GS1
Yarbro, JW1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia[NCT00390897]Phase 4360 participants Interventional2003-07-31Completed
Multicenter Phase 2 Study of Efficacy and Safety of Pegylated Interferon-alfa 2a in Polycythemia Vera Patients[NCT00241241]Phase 240 participants Interventional2004-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

24 reviews available for hydroxyurea and Leukemia

ArticleYear
Case and review: Cutaneous involvement by chronic neutrophilic leukemia vs Sweet syndrome- A diagnostic dilemma.
    Journal of cutaneous pathology, 2021, Volume: 48, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Decitabine; Diagnosis, Di

2021
The management of hyperleukocytosis in 2017: Do we still need leukapheresis?
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2018, Volume: 57, Issue:1

    Topics: Acute Disease; Female; Humans; Hydroxyurea; Induction Chemotherapy; Leukapheresis; Leukemia; Leukocy

2018
[Hydroxyurea (hydroxycarbamide)-induced hepatic dysfunction confirmed by drug-induced lymphocyte stimulation test].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:1

    Topics: Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Fatal Outcome; Humans; Hydroxyurea; I

2014
Management of Hypereosinophilic Syndromes.
    Immunology and allergy clinics of North America, 2015, Volume: 35, Issue:3

    Topics: Adrenal Cortex Hormones; Eosinophils; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesy

2015
Advances in the use of hydroxyurea.
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Adult; Anemia, Sickle Cell; Animals; Arterial Occlusive Diseases; Bone Marrow Diseases; Child; Clini

2009
Hyperleukocytosis, leukostasis and leukapheresis: practice management.
    Blood reviews, 2012, Volume: 26, Issue:3

    Topics: Acute Disease; Humans; Hydroxyurea; Induction Chemotherapy; Leukapheresis; Leukemia; Leukocyte Count

2012
The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
    Seminars in hematology, 2004, Volume: 41, Issue:2 Suppl 3

    Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Disease Progression; Female;

2004
Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders.
    Blood, 2006, Mar-15, Volume: 107, Issue:6

    Topics: Cell Transformation, Neoplastic; Humans; Hydroxyurea; Leukemia; Myeloproliferative Disorders; Nitric

2006
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2

    Topics: Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interfero

2006
Treatment of polycythemia vera.
    Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2

    Topics: Antineoplastic Agents; Aspirin; Female; Humans; Hydroxyurea; Interferons; Janus Kinase 2; Leukemia;

2006
Evolving management of essential thrombocythaemia.
    European journal of haematology. Supplementum, 2007, Issue:68

    Topics: Cell Transformation, Neoplastic; Humans; Hydroxyurea; Leukemia; Thrombocythemia, Essential; Thrombos

2007
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Leukemia & lymphoma, 1996, Volume: 22 Suppl 1

    Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B

1996
Treatment of essential thrombocythemia with special emphasis on leukemogenic risk.
    Annals of hematology, 1999, Volume: 78, Issue:9

    Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia; Middle Aged; Risk Factors; Thrombocytosis; Thr

1999
Treatment of the myeloproliferative disorders with 32P.
    European journal of haematology, 2000, Volume: 65, Issue:1

    Topics: Adult; Aged; Alkylating Agents; Chlorambucil; Clinical Trials as Topic; Combined Modality Therapy; D

2000
A clinical update in polycythemia vera and essential thrombocythemia.
    The American journal of medicine, 2000, Aug-01, Volume: 109, Issue:2

    Topics: Age Factors; Carcinogens; Cell Transformation, Neoplastic; Chronic Disease; Enzyme Inhibitors; Femal

2000
[Polycythemia vera: current status of therapy].
    Deutsche medizinische Wochenschrift (1946), 2000, Oct-13, Volume: 125, Issue:41

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bloodletting; Clinical Trials

2000
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
    Pathologie-biologie, 2001, Volume: 49, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Cell Transformation, Neoplastic; Cohort Studies; Female; Fol

2001
Management of patients with essential thrombocythemia: current concepts and perspectives.
    Pathologie-biologie, 2001, Volume: 49, Issue:2

    Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr

2001
[Essential thrombocythemia: conventional therapy].
    Haematologica, 1991, Volume: 76 Suppl 3

    Topics: Adult; Antineoplastic Agents; Busulfan; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Immunolo

1991
Essential thrombocythemia.
    Progress in hemostasis and thrombosis, 1991, Volume: 10

    Topics: Abortion, Habitual; Age Factors; Blood Platelets; Combined Modality Therapy; Diagnosis, Differential

1991
Purine metabolism as a target for leukemia chemotherapy.
    Blood reviews, 1989, Volume: 3, Issue:3

    Topics: Antineoplastic Agents; Drugs, Investigational; Humans; Hydroxyurea; Leukemia; Mercaptopurine; Methot

1989
[Chemotherapy of chronic leukemias].
    Polskie Archiwum Medycyny Wewnetrznej, 1974, Volume: 51, Issue:3

    Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Chronic Disease; Cyclophosphamide; Humans; Hydroxyure

1974
Chemotherapy and the life cycle of leukaemic cells. A comparison between the growth characteristics of human acute leukaemia and the murine leukaemia L 1210.
    Folia medica Neerlandica, 1969, Dec-02, Volume: 12, Issue:2

    Topics: Anilides; Animals; Cell Division; Cyclophosphamide; Cytarabine; DNA, Neoplasm; Fluorouracil; Humans;

1969
[Cytostatic therapy of acute leukemia (review of the literature)].
    Problemy gematologii i perelivaniia krovi, 1969, Volume: 14, Issue:7

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Drug

1969

Trials

9 trials available for hydroxyurea and Leukemia

ArticleYear
Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study.
    Journal of pediatric hematology/oncology, 2008, Volume: 30, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Cytarabine; Humans; Hydroxyurea; Infections; Leukemia; L

2008
Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
    Neoplasma, 1980, Volume: 27, Issue:1

    Topics: Adult; Aged; Azacitidine; Bone Marrow; Clinical Trials as Topic; Drug Therapy, Combination; Humans;

1980
Immunotherapy maintenance in acute non-lymphocytic leukaemia.
    Australian and New Zealand journal of medicine, 1982, Volume: 12, Issue:6

    Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B

1982
Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.
    European journal of haematology, 1994, Volume: 52, Issue:3

    Topics: Acute Disease; Adult; Aged; Bone Marrow; Humans; Hydroxyurea; Leukemia; Middle Aged; Myeloproliferat

1994
Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
    Nouvelle revue francaise d'hematologie, 1993, Volume: 35, Issue:5

    Topics: Acute Disease; Bloodletting; Combined Modality Therapy; Humans; Hydroxyurea; Leukemia; Phosphorus Ra

1993
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
    British journal of haematology, 2000, Volume: 110, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busul

2000
[Treatment of polycythemia. I--Using radiophosphorus with or without treatment in 483 patients over 65 years of age].
    Annales de medecine interne, 1998, Volume: 149, Issue:2

    Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Female; Humans; Hydroxyurea; Leukemia; Male; Pho

1998
Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.
    International journal of hematology, 2002, Volume: 75, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chromosomes, Human, Pai

2002
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Seminars in hematology, 1986, Volume: 23, Issue:2

    Topics: Acute Disease; Age Factors; Bloodletting; Chlorambucil; Combined Modality Therapy; False Positive Re

1986

Other Studies

73 other studies available for hydroxyurea and Leukemia

ArticleYear
Angiokeratoma-like purpuric palmar nodules following chemotherapy.
    Dermatology online journal, 2021, Aug-15, Volume: 27, Issue:8

    Topics: Angiokeratoma; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis,

2021
Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
    Annals of hematology, 2021, Volume: 100, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Agents; Aspirin; Child; Female; Fibrinolytic Agents; Follow-Up Stu

2021
Image Gallery: A case of chronic eosinophilic leukaemia.
    The British journal of dermatology, 2017, Volume: 177, Issue:4

    Topics: Aged; Antineoplastic Agents; Exanthema; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Leukemia; M

2017
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
    Acta pharmacologica Sinica, 2009, Volume: 30, Issue:10

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combine

2009
Synthesis, antitumor evaluation and crystal structure of hydroxyurea derivatives.
    Chemical & pharmaceutical bulletin, 2010, Volume: 58, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Humans; Hyd

2010
[NKG2D-mediated natural killer cell cytotoxicity against myeloid leukemia cells OUN-1].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2012, Volume: 33, Issue:6

    Topics: Cell Line, Tumor; Humans; Hydroxyurea; Killer Cells, Natural; Leukemia; Ligands; NK Cell Lectin-Like

2012
Tumor lysis syndrome induced by hydroxyurea therapy for leukemic transformation of polycythemia vera.
    American journal of hematology, 2002, Volume: 71, Issue:3

    Topics: Aged; Cell Transformation, Neoplastic; Humans; Hydroxyurea; Leukemia; Male; Polycythemia Vera; Tumor

2002
Long-term use of hydroxyurea for sickle cell anemia.
    JAMA, 2003, Aug-13, Volume: 290, Issue:6

    Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Leukemia; Myelodysplastic Syndromes

2003
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
    American journal of hematology, 2003, Volume: 74, Issue:1

    Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma

2003
HYDROXYUREA: MECHANISM OF ACTION.
    Science (New York, N.Y.), 1963, Nov-22, Volume: 142, Issue:3595

    Topics: Blood Chemical Analysis; Chromatography; Humans; Hydroxamic Acids; Hydroxyurea; Leukemia; Leukemia,

1963
TRIAL OF HYDROXYUREA (NSC-32065) IN CANCER IN CHILDREN.
    Cancer chemotherapy reports, 1964, Volume: 37

    Topics: Antineoplastic Agents; Busulfan; Child; Cyclophosphamide; Dactinomycin; Humans; Hydroxyurea; Leukemi

1964
HYDROXYUREA. A NEW TYPE OF POTENTIAL ANTITUMOR AGENT.
    Journal of medicinal chemistry, 1963, Volume: 6

    Topics: Animals; Antineoplastic Agents; Hydroxyurea; Leukemia; Leukemia L1210; Leukemia, Experimental; Mice;

1963
PEDIATRIC CLINICAL TRIALS WITH HYDROXYUREA (NSC-32065).
    Cancer chemotherapy reports, 1964, Volume: 40

    Topics: Adolescent; Antineoplastic Agents; Child; Drug Therapy; Hodgkin Disease; Hydroxyurea; Leukemia; Neop

1964
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: LEUKEMIA.
    Cancer chemotherapy reports, 1964, Volume: 40

    Topics: Antineoplastic Agents; Drug Therapy; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; L

1964
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: CLINICAL EVALUATION.
    Cancer chemotherapy reports, 1964, Volume: 40

    Topics: Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leu

1964
ANTILEUKEMIC ACTIVITY OF HYDROXYUREA (NSC-32065) AND OTHER UREA DERIVATIVES.
    Cancer chemotherapy reports, 1964, Volume: 40

    Topics: Antineoplastic Agents; Biological Assay; Hydroxyurea; Leukemia; Leukemia, Experimental; Mice; Resear

1964
Malignancy in patients with sickle cell disease.
    American journal of hematology, 2003, Volume: 74, Issue:4

    Topics: Adolescent; Adult; Age of Onset; Anemia, Sickle Cell; Child; Child, Preschool; Data Collection; Huma

2003
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
    International journal of hematology, 2004, Volume: 79, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Division; Cell Line, Tumor; Cytarabine; Daunorub

2004
Impaired DNA replication within progenitor cell pools promotes leukemogenesis.
    PLoS biology, 2005, Volume: 3, Issue:12

    Topics: Animals; Cell Transformation, Neoplastic; Cells, Cultured; DNA; DNA Replication; E2F1 Transcription

2005
Acute biphenotypic leukemia arising in a patient with essential thrombocythemia.
    American journal of hematology, 2006, Volume: 81, Issue:8

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes,

2006
Two-step cell-death kinetics in vitro during cis-platinum, hydroxyurea and mitomycin incubation.
    Cell and tissue kinetics, 1984, Volume: 17, Issue:6

    Topics: Antibiotics, Antineoplastic; Cell Line; Cell Survival; Cisplatin; Flow Cytometry; Humans; Hydroxyure

1984
Treatment of polycythemia vera with hydroxyurea.
    American journal of hematology, 1984, Volume: 17, Issue:4

    Topics: Acute Disease; Aged; Bone Marrow; Female; Humans; Hydroxyurea; Leukemia; Leukopenia; Male; Middle Ag

1984
Phase I trial of cytarabine and hydroxyurea.
    Cancer treatment reports, 1983, Volume: 67, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Child; Cy

1983
Modulation of the cellular pharmacology and clinical toxicity of 1-beta-D-arabinofuranosylcytosine.
    Medical and pediatric oncology, 1982, Volume: 10 Suppl 1

    Topics: Arabinofuranosylcytosine Triphosphate; Cell Line; Cytarabine; Deoxyribonucleotides; DNA; Drug Therap

1982
Acral erythema and hydroxyurea.
    Annals of internal medicine, 1983, Volume: 98, Issue:5 Pt 1

    Topics: Aged; Female; Humans; Hydroxyurea; Leukemia; Raynaud Disease

1983
Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Cancer research, 1982, Volume: 42, Issue:7

    Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cell Division; Cell Line; Cells, Cultured

1982
Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up.
    Cancer, 1982, Oct-15, Volume: 50, Issue:8

    Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined

1982
Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells.
    Cytometry, 1995, Jul-01, Volume: 20, Issue:3

    Topics: Abelson murine leukemia virus; Antineoplastic Agents; Apoptosis; Cell Nucleus; DNA Damage; DNA Nucle

1995
Hydroxyurea and sickle cell crisis.
    The New England journal of medicine, 1995, Oct-12, Volume: 333, Issue:15

    Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leukemia; Randomized Controlled Trials as Topic

1995
Hydroxyurea and sickle cell crisis.
    The New England journal of medicine, 1995, Oct-12, Volume: 333, Issue:15

    Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leukemia; Pain; Polycythemia Vera

1995
The combination of hydroxyurea and leucapheresis in the treatment of chronic myeloid leukaemia in pregnancy.
    Clinical and laboratory haematology, 1993, Volume: 15, Issue:1

    Topics: Adult; Combined Modality Therapy; Female; Humans; Hydroxyurea; Immunologic Factors; Incidence; Infan

1993
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    American journal of hematology, 1996, Volume: 52, Issue:1

    Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic;

1996
Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature.
    Hematology and cell therapy, 1997, Volume: 39, Issue:1

    Topics: Aged; Antisickling Agents; Cell Transformation, Neoplastic; Chromosome Aberrations; Female; Humans;

1997
Different effects of an oligonucleotide uptake stimulating protein on leukemic cells in their primitive and differentiated state.
    FEBS letters, 1998, Jul-03, Volume: 430, Issue:3

    Topics: Biological Transport; Cell Differentiation; Cell Division; Cytarabine; DNA-Binding Proteins; Fungal

1998
Leukemic transformation in polycythemia Vera. MPD(UK) Study Group.
    Blood, 1998, Sep-01, Volume: 92, Issue:5

    Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia; Pipobroman; Polycythemia Vera

1998
Multifactorial mechanisms of drug resistance in tumor cell populations selected for resistance to specific chemotherapeutic agents.
    Advances in enzyme regulation, 1998, Volume: 38

    Topics: Animals; Antineoplastic Agents; Cell Division; Deoxyadenosines; Drug Resistance; Enzyme Inhibitors;

1998
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2000, Volume: 6, Issue:1

    Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free

2000
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
    Leukemia & lymphoma, 2000, Volume: 37, Issue:3-4

    Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro

2000
Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
    Leukemia, 2001, Volume: 15, Issue:1

    Topics: Adult; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; HL-60 Cells; Humans; Hydroxyure

2001
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
    Blood, 2001, Apr-01, Volume: 97, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Int

2001
[Hydroxyurea--is it a harmless drug in Vaquez disease?]].
    Pathologie-biologie, 2001, Volume: 49, Issue:2

    Topics: Aged; Alopecia; Combined Modality Therapy; Cystitis; Erectile Dysfunction; Female; Fever; Follow-Up

2001
[How should patients with essential thrombocythemia be treated?].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2001, Volume: 42, Issue:6

    Topics: Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hydroxyurea; Leukemia; Platelet Aggregation Inh

2001
Is hydroxyurea leukemogenic in children with sickle cell disease?
    Blood, 2001, Nov-01, Volume: 98, Issue:9

    Topics: Adolescent; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Leukemia

2001
Erythroid differentiation in cultured Friend leukemia cells treated with metabolic inhibitors.
    Cancer research, 1976, Volume: 36, Issue:5

    Topics: 5-Aminolevulinate Synthetase; Antimetabolites; Cell Differentiation; Cell Line; Clone Cells; Cyclohe

1976
Extreme leucocytosis and prognosis of newly diagnosed patients with acute non-lymphocytic leukaemia.
    The Medical journal of Australia, 1979, Jun-02, Volume: 1, Issue:11

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Hu

1979
Philadelphia-chromosome-positive pre-B-cell leukemia presenting as blast crisis of chronic myelogenous leukemia.
    Blood, 1979, Volume: 54, Issue:5

    Topics: B-Lymphocytes; Cell Transformation, Neoplastic; Child; Chromosomes, Human, 21-22 and Y; Humans; Hydr

1979
Non-Hodgkin's lymphoma in children: results of treatment with LSA2-L2 protocol.
    The British journal of cancer. Supplement, 1975, Volume: 2

    Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Neoplasms; Child; Child, Preschool; Cyclophosp

1975
The place of research in hospital medicine.
    The New Zealand medical journal, 1975, Sep-10, Volume: 82, Issue:547

    Topics: Acute Disease; Australia; Cell Division; History, 20th Century; Hospital Administration; Hospitals,

1975
Eosinophilic leukemia. Remission with vincristine and hydroxyurea.
    The American journal of medicine, 1975, Volume: 59, Issue:2

    Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Eosinophils; Humans; Hydroxyurea; Le

1975
Treatment of basophilic leukemia in a dog.
    Journal of the American Veterinary Medical Association, 1975, Feb-15, Volume: 166, Issue:4

    Topics: Animals; Basophils; Bone Marrow; Bone Marrow Cells; Busulfan; Dog Diseases; Dogs; Erythrocyte Count;

1975
Non-aggressive therapy for chronic myeloid leukaemia in blastic transformation.
    Cancer chemotherapy and pharmacology, 1992, Volume: 29, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot

1992
Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
    American journal of hematology, 1990, Volume: 33, Issue:2

    Topics: Acute Disease; Female; Humans; Hydroxyurea; Leukemia; Middle Aged; Myelodysplastic Syndromes; Thromb

1990
Leukemic transformation in polycythemia vera: analysis of risk factors.
    American journal of hematology, 1990, Volume: 34, Issue:1

    Topics: Acute Disease; Female; Humans; Hydroxyurea; Leukemia; Male; Middle Aged; Polycythemia Vera; Retrospe

1990
Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease.
    Cancer genetics and cytogenetics, 1990, Oct-01, Volume: 49, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chronic Disease; Female; Humans; Hydroxyurea

1990
Modulation of transferrin receptor expression by inhibitors of nucleic acid synthesis.
    Journal of cellular physiology, 1985, Volume: 124, Issue:1

    Topics: Animals; Cell Line; Cell Survival; Deferoxamine; DNA Replication; Flow Cytometry; Fluorescence; Huma

1985
Differential modulation of 1-beta-D-arabinofuranosylcytosine metabolism by hydroxyurea in human leukemic cell lines.
    Biochemical pharmacology, 1988, May-01, Volume: 37, Issue:9

    Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; B-Lymphocytes; Cell Line; Cytarabine; Deo

1988
Ara-CTP metabolism following hydroxyurea or methotrexate treatment in human leukemia cell lines.
    Advances in experimental medicine and biology, 1989, Volume: 253B

    Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Deoxycytidine; Deoxycytosine

1989
Acute leukemia in polycythemia vera.
    Seminars in hematology, 1986, Volume: 23, Issue:2

    Topics: Acute Disease; Antigens, Neoplasm; Bloodletting; Chlorambucil; Chromosome Aberrations; Chromosome Di

1986
Elevated glucocorticoid receptor binding in cultured human lymphoblasts following hydroxyurea treatment: lack of effect on steroid responsiveness.
    Cancer research, 1986, Volume: 46, Issue:8

    Topics: Cell Cycle; Cell Survival; Cells, Cultured; Dexamethasone; DNA; Glucocorticoids; HeLa Cells; Humans;

1986
Long-term management of polycythemia vera with hydroxyurea: a progress report.
    Seminars in hematology, 1986, Volume: 23, Issue:3

    Topics: Drug Administration Schedule; Humans; Hydroxyurea; Leukemia; Polycythemia Vera; Thrombosis

1986
Effect of 1-beta-D-arabinofuranosyl cytosine and hydroxyurea on the repair of X-ray-induced DNA single-strand breaks in human leukemic blasts.
    Biochemical pharmacology, 1985, Jul-15, Volume: 34, Issue:14

    Topics: Cells, Cultured; Cytarabine; DNA; DNA Repair; DNA, Single-Stranded; Humans; Hydroxyurea; Leukemia; X

1985
Combination chemotherapy of adult acute nonlymphoblastic leukemia.
    Annals of internal medicine, 1972, Volume: 76, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Bone Marrow; Cytarabine; Drug Synergism; Female; Humans; Hyd

1972
Selective toxicity of rifamycin derivatives for leukaemic human leucocytes.
    Nature: New biology, 1972, Apr-12, Volume: 236, Issue:67

    Topics: Antibiotics, Antineoplastic; Bone Marrow; Bone Marrow Cells; Carbon Isotopes; Cell Differentiation;

1972
[Clinical trial of chemotherapeutic combinations based on the notion of attempted cellular synchronization. Preliminary administration of an antimitotic followed by the use of cycle-dependent or phase dependent product(s)].
    La Nouvelle presse medicale, 1972, Jun-24, Volume: 1, Issue:26

    Topics: Amino Sugars; Anthraquinones; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Daunorubicin; D

1972
The outlook for the adult with acute leukaemia, 1972.
    The Medical journal of Australia, 1972, Aug-19, Volume: 2, Issue:8

    Topics: Acute Disease; Adolescent; Adult; Aged; Bacterial Infections; Cytarabine; Drug Combinations; Female;

1972
Optimism in leukemia treatment.
    Canadian Medical Association journal, 1973, Apr-07, Volume: 108, Issue:7

    Topics: Acute Disease; Adult; Child; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; Leukemia,

1973
Proceedings: Treatment of acute leukaemia in adults.
    The Medical journal of Australia, 1974, Jun-29, Volume: 1, Issue:26

    Topics: Acute Disease; Adult; Allopurinol; Anti-Bacterial Agents; Bacterial Infections; Child; Cytarabine; D

1974
Comparative results obtained in the treatment of acute leukemia.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1973, Volume: 43

    Topics: Antineoplastic Agents; Asparaginase; Carmustine; Cytarabine; Daunorubicin; Drug Therapy, Combination

1973
The effects of leukemia and lymphoma chemotherapy on hematopoietic cells.
    The American journal of medical technology, 1973, Volume: 39, Issue:5

    Topics: Alkylating Agents; Antimetabolites; Antineoplastic Agents; Asparaginase; Cell Division; Daunorubicin

1973
[Repair synthesis of DNA in normal and leukemic lymphocytes damaged by an alkylating agent. Inhibition of repair synthesis by caffeine. Preliminary report].
    Schweizerische medizinische Wochenschrift, 1974, Jan-26, Volume: 104, Issue:4

    Topics: Alkylating Agents; Caffeine; Cells, Cultured; DNA; DNA Repair; Humans; Hydroxyurea; Leukemia; Lympho

1974
[Personal experience on the chemotherapy of leukemias and hematosarcomas].
    Acta geneticae medicae et gemellologiae, 1968, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Drug Synergism; Hodgkin Disease; Humans; Hydrazines; Hydroxyurea; Leukemia; L

1968
Drugs in the treatment of leukemia.
    British medical journal, 1968, Nov-02, Volume: 4, Issue:5626

    Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; L

1968
Hydroxyurea in the treatment of chronic myeloid leukemia.
    Southern medical journal, 1971, Volume: 64, Issue:2

    Topics: DNA; Humans; Hydroxyurea; Leukemia; Leukocytosis; Middle Aged; Splenomegaly

1971